Obesity is one of the most urgent global health challenges, affecting more than 650 million adults worldwide. Current treatment pathways leave a significant gap between medical management such as GLP-1 therapy and invasive bariatric surgery. ESG is emerging as a minimally invasive alternative, addressing patients with obesity (BMI 30–40 kg/m²) who have not achieved success with conservative measures such as diet, exercise, or medication.

By automating suturing, EndoZip transforms ESG into a scalable, single-physician, fast, outpatient procedure with a short learning curve. Unlike current manual suturing systems that demand two physician operators, longer procedure times, and advanced endoscopic skills, EndoZip delivers unmatched efficiency, reproducibility, and economics – democratizing ESG and expanding access to bariatric surgeons while setting a new standard for care.

“CE Mark approval of EndoZip is a pivotal milestone for Nitinotes,” said Lloyd Diamond, Chief Executive Officer of Nitinotes. “This achievement validates the safety and performance of our technology and paves the way for commercialization in Europe. With EndoZip, we have the potential to dramatically expand patient access to a safe, durable, minimally invasive obesity treatment while creating significant value for providers and healthcare systems.”